<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00905723</url>
  </required_header>
  <id_info>
    <org_study_id>0759/08</org_study_id>
    <nct_id>NCT00905723</nct_id>
  </id_info>
  <brief_title>The Effects of Isoflavone and Estrogen in Sex Response in Climacteric Women</brief_title>
  <official_title>Effects of Isoflavone and Estrogen in Sex Response in Climacteric Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Federal University of São Paulo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Federal University of São Paulo</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Climacterium is marked by hypoestrogenism and it is associated to drastic vasomotors
      symptoms, genital atrophy and humor alteration. Additionally, these symptoms impair sexual
      life and life quality. These effects can be counteracted by administration of estrogen
      therapy. However, estrogen therapy has side effects and isoflavone has been proposed as an
      estrogen substitute in reposition therapy. The aim of the randomized controlled trial is to
      evaluate the effects of isoflavone in the sex life assessed by a modified McCoy's sexual
      questionnaire.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2009</start_date>
  <primary_completion_date type="Anticipated">May 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>McCoy's sexual questionnaire</measure>
    <time_frame>at recruitment and six months later</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Kupperman's index</measure>
    <time_frame>at recruitment and six months later</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Postmenopausal Symptoms</condition>
  <arm_group>
    <arm_group_label>Estrogen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Women randomized to this group will receive daily pills containing 1 mg of estradiol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Isoflavone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Women randomized to this group will receive daily pills of 150 mg isoflavone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Women randomized to this group will be administered daily placebo pills</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>estradiol</intervention_name>
    <description>1 mg daily for 6 months</description>
    <arm_group_label>Estrogen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>isoflavone</intervention_name>
    <description>150 mg isoflavone daily for 6 months</description>
    <arm_group_label>Isoflavone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>sugar pill daily for six months</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  women aged 45-65 years old

          -  presenting climacteric symptoms

          -  sexual complaints

        Exclusion Criteria:

          -  hormonal therapy

          -  counter indication to hormonal therapy

          -  uncontrolled comorbidities
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mauro A Aidar, M.D., PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Universidade Federal de São Paulo</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Teresa R Embiruçu, M.D.</last_name>
    <phone>5511-75413521</phone>
    <email>embirucu2@yahoo.com.br</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Regiane HB Rabelo, M.D.</last_name>
    <phone>5511-72307128</phone>
    <email>gianehelena@ig.com.br</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ambulatório de Ginecologia Endócrina</name>
      <address>
        <city>São Paulo</city>
        <zip>04039-060</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Cecília Santos, Nurse</last_name>
      <phone>5511-55496174</phone>
      <email>mc.santos@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Teresa R Embiruçu, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <link>
    <url>http://www.unifesp.br</url>
    <description>Universidade Federal de São Paulo's web page</description>
  </link>
  <verification_date>May 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 19, 2009</study_first_submitted>
  <study_first_submitted_qc>May 19, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 20, 2009</study_first_posted>
  <last_update_submitted>May 19, 2009</last_update_submitted>
  <last_update_submitted_qc>May 19, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 20, 2009</last_update_posted>
  <responsible_party>
    <name_title>Teresa Raquel Embiruçu de Araújo</name_title>
    <organization>Universidade Federal de São Paulo - Departamento de Ginecologia</organization>
  </responsible_party>
  <keyword>climacterium</keyword>
  <keyword>sexual life</keyword>
  <keyword>isoflavone</keyword>
  <keyword>estrogen</keyword>
  <keyword>McCoy's sexual questionnaire</keyword>
  <keyword>Kupperman index</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Polyestradiol phosphate</mesh_term>
    <mesh_term>Estrogens</mesh_term>
    <mesh_term>Estradiol 3-benzoate</mesh_term>
    <mesh_term>Estradiol 17 beta-cypionate</mesh_term>
    <mesh_term>Estradiol valerate</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>April 11, 2016</submitted>
    <returned>May 16, 2016</returned>
    <submitted>May 23, 2016</submitted>
    <returned>June 29, 2016</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

